DS Biopharma Names Leopoldo Zambeletti To Board
This article was originally published in Scrip
DS Biopharma, a privately held biopharmaceutical company, has appointed Leopoldo Zambeletti to its board as non-executive director. As an investment banker, Zambeletti led the European Health Investment team at JP Morgan after which he held the same position at Credit Suisse. Since 2013, Zambeletti has been an independent strategic advisor to life science companies and is also non-executive director of Nogra Pharma, Advanced Accelerator Applications, Faron Pharmaceuticals, Summit Therapeutics Plc., and is an advisor and co-founder to the US medtech company Qardio.